Objective: To study the pharmacokinetic parameters of a once-daily regimen of amikacin (15 mg/kg) in association with other antimicrobial agents in 35 children with severe Gram-negative infections.
INTRODUCTION
Aminoglycoside antibiotics are very important, in association with other antimicrobial agents, in the treatment of Gram-negative infections. A daily regimen administered in a single dose has been effective in several studies. Once-daily regimens of amikacin [l] , netilmicin [2] or gentamicin [3] are less toxic than, and equally efficient as, more frequent administration. The volume of distribution is inversely correlated with age
[4] and is greater in children than in adults [5] . This interpatient variation in volume of distribution has a direct effect on the therapeutic peak levels achieved [6] . Because of this wide variation in pharmacokinetic parameters and the low therapeutic index, aminoglycosides are drugs that require an individualized dosage. A Bayesian forecasting program has been described to adjust the aminoglycoside dosage [7-lo] .
The Bayesian method is a good approach in pehatric patients, because few serum samples per patient are required to estimate the pharmacokinetic parameters for optimizing dosage regimens. The pharmacokinetics of amikacin have been documented in critically 111 [ll] and neutropenic children [12] . While the serum concentrations and the clinical efficacy of amikacin have been studied in children with severe Gramnegative infections [13, 14] , no information has been reported on amikacin pharmacokinetics in these patients. Therefore, the aim of this study was to investigate the pharmacokinetics (in terms of dosage, concentrations achieved and pharmacokmetic parameters) and to evaluate the toxicity of a once-daily amikacin regimen (15 mg/kg per day) in pediatric patients, as well as the Bayesian forecasting method for predicting serum amikacin concentrations. presumed infection, were included in the study. Severe infections were defined as follows: pyelonephritis (n= 12), pulmonary infection (n=4), meningitis (n=5), febrile syndrome in AIDS (n = 2), bacteraemia (n = l), arthritis (n = 3), other locahzed infections (n = 8). Twenty-two bacterial isolates were identified as responsible: Escherichia coli(n = lo), Aeudomonus aeruginosa (n =2), Proteus mirabilis (n = l), Staphylococcus spp. (n = 4), Neisseria meningitidis (n = 3), Haemophibs inzuenzae (n = 2).
Drug administration and dosage
Each patient received 15 mg/kg amikacin therapy at doses ranging &om 100 to 750 mg as a 30-min intravenous infusion in 0.9% sodium chloride. Amikacin was given to all patients in once-daily doses combined with one or more other antimicrobial agents. The other drugs co-administered were ceftriaxone (n = 22), cefotaxime (n = 7), ciprofloxacin (n = l), amoxycillin (n = 3), oxacillin (n = l), teicoplanin (n = 1) and fosfomycin (n = 3). For inclusion, all patients had to receive amikacin for a minimum of 5 days. Venous blood samples were collected from an indwelling catheter in the non-infused forearm just before infusion (trough) and 30 min after the end of infusion (peak). Blood samples for follow-up peak and trough amikacin concentrations were obtained at days 2 and 5. On day 2, the amikacin dosage was adjusted to achieve a peak level of 230 mg/L and a trough level < 5 mg/L. On day 5, peak and trough samples were collected, to ensure that the actual levels in the serum were in fact close to the calculated levels. Two pairs of peak and trough values were required for each patient for inclusion in the study. Serum concentrations of amikacin were determined by a fluorescence polarization immunoassay (TDx, Abbott Diagnostic Division, Rungis, France). The sensitivity of the assay was 0.8 mg/L. Replicate measurements (n = 5 ) of representative samples with concentrations in the region of 5, 10, 20 and 35 mg/L were made in order to determine the mean and the standard deviation of each sample. The error pattern of the TDx assay for amikacin is shown in Figure 1 . The resulting polynomial equation found for this assay is:
where SD represents the standard deviation of the measurement and C represents the measured serum concentration.
Evaluation of nephrotoxicity
The criterion of toxicity was an increase in serum creatinine of 15% or more between days 2 and 5 of the amikacin therapy. Serum amikacin (rngh)
Assay error pattern of the TDx assay for amikacin.
Bayesian forecasting of dosage
The pharmacokinetics of amikacin were described by + (slopex Clcre,,). The coefficients of variation were set at 30% for Vd at 25% for C~N R and at 40% for the slope. Creatinine clearance was estimated by the method of Schwartz et al. [15] .
Predictive analysis
The predictive performance was evaluated by the methods described by Sheiner and Beal [16] . The predicted amikacin serum concentrations were compared with those measured. Bias and precision were assessed, respectively, by mean prediction error (ME) with 95% confidence interval and root mean squared error (RMSE) with the corresponding equations:
where C,,, and C,,l,,, represent the predicted and measured concentrations. The bias was considered significantly different if the 95% confidence interval d d not include zero. A paired t-test between predicted and measured concentrations was used to evaluate their differences. A p-value < 0.05 was considered statistically significant.
RESULTS
The demographic parameters of indvidual children, and the amikacin pharmacohnetic parameters are listed in Table 1 . The half-life of amikacin ranged from 1.1 to 4.4 h. The distribution volume of amikacin varied widely from patient to patient. The mean peak and trough amikacin serum concentrations on days 2 and 5 are shown in Table 2 . The measured serum concentrations showed large interindividual variations. O n day 2, 100% of the chddren had trough levels < 5 mg/L, 54% of which were below the limit of detection of the assay. O n day 5, two children had a trough level > 5 mg/L (6.1 and 8.1 mg/L). To achieve therapeutic concentrations between 30 and 40 mg/L, individual dosage was necessary in 19 of 35 children. The dose required was higher than the recommended dose of 15 mg/kg, with a mean of 21 mg/kg. Measured and predicted serum amikacin concentrations at both peak (n = 35) and trough (n = 35) were compared in all patients &om whom samples were available on day 5. The bias and precision of Bayesian predictive performance are shown in Table 3 
DISCUSSION
The once-daily dosage regimen resulted in a higher peak and a lower trough level. Of the patients 46% and 14% had peaks of > 30 mg/L and > 40 mg/L, respectively, and 100% had a trough < 2.5 mg/L on day 2. No significant difference was noted between the mean peak and trough amikacin serum concentrations observed on days 2 and 5. There was no tendency for amikacin accumulation during treatment. The mean and individual peak amikacin levels in our study were lower than those previously reported in adult patients with severe infections [17, 18] or in healthy young adult volunteers (23 to 31 years) [19] receiving a similar dose of amikacin. These results could be explained by a greater volume of distribution and a more rapid total clearance in pediatric patients. These results, however, are comparable with those observed in critically ill patients over the age of 1 year (33.7 k 4.8 mg/L [ l l ] and in pediatric patients receiving 20 mg/kg who were suffering from severe Gramnegative infections (36.5 4 9.1 mg/L [13] ). However, the once-daily dosage allows the maintenance of higher aminoglycoside peak levels than conventional regimens. Moore et al. [20] demonstrated in patients with severe Gram-negative infections that a high peak concentration relative to the MIC is a major determinant of the clinical response to aminoglycoside therapy. High peak levels are effective, because the bactericidal activity of aminoglycosides is concentration dependent, but the ideal therapeutic peak has not been defined. Beaucaire et al. [21] reported in critically ill adults a significantly higher mortality rate from infection when the first amikacin peak was below 40 mg/L. To achieve a peak value of 40 mg/L on the first day of treatment, a loading dose is required, especially in pediatric patients with large distribution volume. This loading dose could correspond to 25% of the daily dose [22] . Indeed, in neutropenic children [12, 23] and critically ill children [ l l ] , a dose of 20 mg/kg per day has been proposed.
We noted large interindividual variations in the concentrations and pharmacokinetic parameters of amikacin in pediatric patients. Therapeutic drug monitoring early in treatment is thus necessary to optimize dosage regimens. Predictive performance of the Bayesian program can be enhanced when initial population parameters reflect the patient population being monitored. In clinical routine, monitoring of aminoglycosides has been based on both the peak and trough levels. The frequency of these measurements, however, could be reduced to a single sampling. Although trough concentrations are measured to avoid aminoglycoside toxicity, it may be difficult to adjust dosage on the basis of these concentrations, which are currently below the limit of detection of the assay. In neutropenic children undergoing bone marrow transplantation receiving 20 mg/kg per day of amikacin, serum concentrations declined rapidly and became undetectable within 6 h [24] . Therefore, the serum peak level seems the most appropriate sample for monitoring. Sampling at other time intervals has been proposed. Blaser et al. [25] reported a significant correlation between nephrotoxicity and 8-h serum netilmicin concentrations. In comparison with serum gentamicin concentrations 1 h and 8 h after the initial administration, Bayesian analysis using the 4-h concentration was the least biased and the most precise for predicting peak and trough concentrations [26] . However, these stuhes found no relationship between the serum concentrations and therapeutic efficacy.
Our results regarding toxicity should be interpreted cautiously. Nephrotoxicity was defined as a rise of 2 15% in serum creatinine, and no difference was noted between days 2 and 5 . The higher trough concentrations observed on day 5 (6.1 and 8.9 mg/L) were not accompanied by an increase in serum creatinine, and probably reflect wide intrapatient variability in amikacin handling. The fiequency of nephro-and ototoxicity seems to be lower in children than in adults [24] . Other investigations to evaluate ototoxicity must be performed.
In conclusion, once-daily dosage of amikacin (15 mg/kg per day), combined with another antimicrobial agent, is well tolerated in pediatric patients. Serum concentration monitoring early in treatment is essential in children who show wide interpatient variability in pharmacokinetic parameters. Moreover, as it seems that the initial peak value is an important factor in clinical outcome, a loading dose of 20 mg/kg per day is recommended, in order to obtain satisfactory concentrations in most children. Drug monitoring will then indicate whether or not dosage has to be reduced. This approach provides security in achieving the best results in children. Bayesian analysis is suitable for individualization of amikacin dosage for pediatric patients. Indeed, a single non-steady-state concentration is all that is required to adjust dosage early in treatment, preferably in the first 24 h.
